

Hyperbaric Oxygen Therapy

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

The Plan considers Systemic Hyperbaric Oxygen Therapy (HBOT) medically necessary when the criteria below for certain medical conditions are met for a prior authorization review. According to the Undersea and Hyperbaric Medical Society, hyperbaric oxygen therapy applies an increased pressure of ≥ 1 atmosphere absolute at sea level with $\geq 95\%$ oxygen to the body leading to augmented oxygen levels in the blood to accelerate improvement of conditions. There has been FDA clearance of approval for specific indications. Most commonly, it is used to treat chronic complex diabetic wounds of the lower limbs. The Plan does not consider medically necessary the topical application of oxygen under any circumstances.

Definitions

"Hyperbaric Oxygen Therapy" (HBOT) is a method in which the entire body is exposed to oxygen under increased atmospheric pressure.

"Continuous Topical Oxygen Therapy" (CTOT) is a portable unit that can provide continuous flow of atmospheric (normobaric) oxygen to the wound up to 24 hours a day and 7 days a week. This does not require the member to be in-clinic and immobilized for therapy.

“Standard Wound Care” in patients with diabetic wounds includes the assessment of a patient’s vascular status and correction of any vascular problems in the affected limb if possible; optimization of nutritional status, optimization of glucose control; debridement by any means to remove devitalized tissue; maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings; appropriate off-loading; and necessary treatment to resolve any infection that might be present.

Clinical Indications

General Indications

In addition to condition-specific criteria (outlined below), The Plan considers HBOT medically necessary when ALL of the following criteria are met:

1. HBOT must be prescribed and administered by the licensed treating physician; *and*
2. HBOT must be administered in a chamber (such as the single-patient unit or multiplace unit); *and*
3. Continued HBOT is limited to 30 day authorization periods unless otherwise noted in the criteria below. Continued HBOT is subject to review for medical necessity and is indicated only when ALL of the following criteria are met:
 - a. Adherence to hyperbaric oxygen therapy; *and*
 - b. Evidence of improvement during the authorization period, e.g., reduction in the size of wound and reduction in signs of infection and/or inflammation.

Condition-Specific Indications

The Plan considers HBOT medically necessary when General Indications AND at least one of the following indications are met:

1. *Acute air or gas embolism* - 1 treatment may be indicated; additional treatments may be indicated only if symptoms persist.
2. *Acute carbon monoxide poisoning* - 1 to 3 total treatments may be indicated depending on persistence of clinical symptoms.
3. *Acute traumatic peripheral ischemia*, when there is immediate threat of permanent dysfunction, loss of limb, or death.
4. *Anemia*, when ALL of the following criteria are met:
 - a. Patient unable or unwilling to receive a red blood cell transfusion; *and*
 - b. Emergent treatment, as indicated by 1 or more of the following:
 - i. Active hemolysis with progressive anemia; *or*
 - ii. Acute blood loss or active massive hemorrhage; *or*
 - iii. Hypovolemic shock.
5. *Burns* (large or severe burns treated at a specialized burn center).
6. *Central retinal artery occlusion*, when started within 24 hours of symptom onset - Treatment is typically indicated until CRA recanalization has occurred (usually 24-72 hours).
7. *Chronic diabetic ulcer*, when ALL of the following criteria are met:

- a. Severe wound (Wagner Grade III or higher) based on at least ONE of the following criteria:
 - i. Deep ulceration to tendon causing tendonitis or non-infected bone; *or*
 - ii. Deep ulcer with infection (e.g., abscess, osteomyelitis, or joint sepsis); *or*
 - iii. Localized gangrene (ischemia) of the forefoot or heel.
 - b. Prior evaluation and treatment of underlying peripheral vascular and/or neuropathic disease; *and*
 - c. Documented 30-day trial of conventional wound care for diabetes with minimal to no healing and meets ALL of the following:
 - i. Glycemic optimization; *and*
 - ii. Wound is not infected or has been treated with antibiotics.
 - d. Treatment is indicated daily and meets ALL of the following:
 - i. Evaluation of the wound occurs at least every 30 days during HBOT and demonstrates measurable signs of healing; *and*
 - ii. Treatment is ordered for no more than 40 HBOT treatments to allow for review of the evaluation.
8. *Compromised skin grafts or flaps, where hypoxia or decreased perfusion has compromised viability acutely* when ALL of the following criteria are met:
- a. Correctable causes of the flap failure have been explored and adequately addressed prior to initiation of HBOT.
 - b. Treatment is indicated for 2 times per day until the graft or flap appears viable, then 1 time per day until healed.
 - c. Efficacy of therapy should be reviewed after 20 treatments and discontinued if no clinical improvement.
9. *Crush injuries and compartment syndrome*, when there is immediate threat of permanent dysfunction, loss of limb, or death - Treatment is indicated for 7 days or 14 treatment sessions. Treatment typically should occur twice a day for two days, then daily for two days.
10. *Carbon monoxide poisoning, with or without Cyanide poisoning*.
11. *Decompression illness* - Treatment should be rapid and repeated up to 10 times only if symptoms persist.
12. *Idiopathic sudden sensorineural hearing loss* when ALL of the following criteria are met:
- a. Audiometry showing a 30-dB hearing loss at 3 consecutive frequencies; *and*
 - b. Other underlying potential causes have been ruled out or are not applicable; *and*
 - c. HBOT is given in conjunction with standard of care steroid therapy; *and*
 - d. 15 to 20 total treatments may be indicated once daily only when HBOT is initiated within 3 months after onset.
13. *Intracranial abscess* when ALL of the following criteria are met:
- a. The patient has multiple abscesses, abscesses in a deep or dominant location, or is immunocompromised; *and*

- b. The patient has not responded to or is deteriorating despite standard of care, surgical and/or antibiotic treatment; or is not a candidate for surgery due to high risks or contraindications; *and*
 - c. Treatment may be indicated for 1-2 times per day; *and*
 - d. Efficacy of therapy should be reviewed after 20 treatments and discontinued if no clinical improvement.
14. *Necrotizing soft tissue infections and gas gangrene (Clostridial myositis and myonecrosis)*
- a. Documentation from a treating physician stating HBOT is used in conjunction with surgical debridement and antibiotics.
 - b. Treatment is ordered and indicated for 2 times per day until there is no further extension of necrosis in previously debrided areas.
 - c. Efficacy of therapy should be reviewed after 30 treatments and discontinued if no clinical improvement.
15. *Osteomyelitis* when ALL of the following criteria are met:
- a. The diagnosis is confirmed by imaging or biopsy; *and*
 - b. Documentation from a treating physician confirms that the patient is unresponsive to conventional medical and surgical management; and the patient has completed at least 6 weeks of appropriate IV antibiotic therapy, and has undergone surgery without resolution or has documented justification for why surgery is not an option.
16. *Radiation injury*; up to 40 HBOT treatments are indicated, when ONE of the following criteria are met:
- a. Osteoradionecrosis (e.g., radiation-induced osteonecrosis of the jaw) as an adjunct to conventional treatment; *or*
 - b. Soft tissue radionecrosis as an adjunct to conventional treatment; *or*
 - c. Radiation-induced hemorrhagic cystitis; *or*
 - d. Radiation-induced proctitis; *or*
 - e. Prophylactic prevention of osteonecrosis of the jaw following tooth extraction in an irradiated field:
 - i. Prior to surgery, treatment is ordered and indicated for 20 HBOT treatments.
 - ii. Immediately after surgery, treatment is ordered and indicated for 10 HBOT treatments.

Experimental or Investigational / Not Medically Necessary

Absolute Contraindications for Hyperbaric Oxygen

- Concurrent administration of the antibiotic cream mafenide (Sulfamylon)
- Concurrent administration of disulfiram (Antabuse)
- Concurrent administration of antineoplastic agent doxorubicin
- Concurrent or past administration of antineoplastic agents bleomycin or cisplatin (Platinol)
- Premature infants (birth prior to 37 weeks gestation)
- Untreated pneumothorax

Experimental or Investigational

The Plan considers the use of HBOT to be experimental and investigational in the treatment of the following conditions including but not limited to:

- Actinomycosis
- Acute cerebral edema
- Acute coronary syndrome
- Acute or chronic cerebrovascular insufficiency
- Acute thermal and chemical pulmonary damage (i.e., smoke inhalation with pulmonary insufficiency)
- Aerobic infection
- AIDS/HIV
- Alzheimer's disease
- Anaerobic infection other than Clostridial
- Anoxic brain injury
- Arthritic diseases
- Asthma
- Autism
- Bell's palsy
- Cancer
- Cardiogenic shock
- Cerebral palsy
- Chronic fatigue syndrome
- Chronic peripheral vascular insufficiency
- Coronary artery disease
- COVID-19
- Cutaneous, decubitus, and venous stasis ulcers
- Depression
- Fibromyalgia
- Fractures or fracture non-union
- Heart disease
- Hepatic necrosis
- Hepatitis
- Inflammatory bowel disease
- Ischemic stroke
- Lyme disease
- Malignant otitis externa
- Meningioma
- Migraine and cluster headaches
- Multiple sclerosis

- Myocardial infarction
- Non-compromised skin grafts and flaps
- Osteonecrosis of the jaw (not induced by radiation)
- Osteoporosis
- Parkinson's disease
- Post-concussive syndrome
- Pulmonary emphysema
- Following Radiation injuries:
 - Radiation-induced retinitis pigmentosa
 - Radiation-induced retinopathy
 - Radiation-induced neurologic injury
 - Radiation-induced xerostomia
 - Radiation-induced soft tissue injury (unless the above criteria is met)
- Senility
- Sickle cell anemia
- Spinal cord injury
- Stroke
- Surgical wound dehiscence
- Tetanus
- Tinnitus
- Traumatic brain injury
- Vascular dementia

Topical Application of Oxygen

This method of oxygen administration does not meet the definition of HBOT as stated above and there are no high quality evidence-based studies of its use in the literature. In fact, one of the only randomized trials for topical oxygen therapy in diabetic foot ulcers (Leslie et al. 1988) actually demonstrated a trend toward slower healing in the topical oxygen group. A recent small, randomized control trial (Yu et al. 2016) claimed a significant difference in healing rates between patients receiving topical oxygen therapy and those receiving standard wound care. However, the study was underpowered and it is unclear how many patients were included in each of the ulcer "stage" groups and statistical analysis is lacking. Another small prospective study (Blackman et al. 2010) showed possible improvement in healing with topical oxygen compared to a silver-based dressing but was neither randomized nor blinded. In addition, a small case series of 3 patients (Agarwal et al. 2015) described a device for applying topical oxygen and stated that these patients required fewer debridements, but there was no control group. A larger, multi-center study (Dryden et al. 2016) evaluated topical oxygen gel for both acute and chronic wounds with delayed healing, but again was simply observational and did not compare outcomes to any control group. In 2021, Hayes rates topical oxygen therapy for chronic wound healing as D2. Overall, current evidence is limited and consists of small, low quality studies that support the categorization of topical

oxygen therapy as experimental and investigational. Investigational and experimental treatments are not covered by the Plan. Topical HBOT includes boot or bag systems and single limb or sacral chambers.

Applicable Billing Codes

CPT/HCPCS Codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
99183	Physician attendance and supervision of hyperbaric oxygen therapy, per session
G0277	Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
ICD-10 codes <i>considered experimental or investigational</i> :	
A00 - A04.6; A04.8 - A05.1; A05.3 - A99; B00.0 - B96.6; B96.8 - B99; L08.0, L08.81 - L08.9; L44.4; L88, L98.0	Infectious diseases other than clostridium [aerobic and nonaerobic infections]
A01.04	Typhoid arthritis [arthritic diseases]
A02.23	Salmonella arthritis [arthritic diseases]
A18.02	Tuberculous arthritis of other joints [arthritic diseases]
A33 - A35	Tetanus
A39.83	Meningococcal arthritis [arthritic diseases]
A39.84	Postmeningococcal arthritis [arthritic diseases]
A42.0-A42.9	Actinomycosis
A54.42	Gonococcal arthritis [arthritic diseases]
A69.20 - A69.9	Lyme Disease
A69.23	Arthritis due to Lyme disease [arthritic diseases]
B06.82	Rubella arthritis [arthritic diseases]
B26.85	Mumps arthritis [arthritic diseases]

B42.82	Sporotrichosis arthritis [arthritic diseases]
C00.00 - C96.9	Malignant neoplasms [cancer]
D00.00 - D09.9	In situ neoplasms [cancer]
D32.0, D32.1, D32.9, D42.0 - D42.9	Benign neoplasm of meninges, Neoplasm of uncertain behavior of meninges
D57.00 - D57.819	Sickle-cell disorders
F01.50 - F01.C4	Vascular dementia
F07.81	Postconcussional syndrome
F32.0 - F33.9	Depression
F84.0	Autistic disorder
G30.0 - G30.8	Alzheimer's disease
G35	Multiple sclerosis
G43.001 - G43.919	Migraine
G44.001 - G44.029	Cluster headaches
G51.0	Bell's palsy
G62.82	Radiation-induced polyneuropathy
G80.0 - G80.9	Cerebral Palsy
G93.1	Anoxic brain damage, not elsewhere classified
G98.0	Neurogenic arthritis, not elsewhere classified [arthritic diseases]
H31.021 - H31.029	Solar retinopathy
H60.20 - H60.23	Malignant Otitis Externa

H93.11 - H93.19	Tinnitus
I21.01 - I22.9	Myocardial Infarction
I24.9	Acute ischemic heart disease, unspecified
I25.10 - I25.119	Coronary artery disease
I25.700 - I25.799; I25.811 - I25.84; I25.9	Atherosclerotic heart disease of coronary artery bypass grafts [coronary artery disease]
I63.0 - I63.9	Cerebral infarction [ischemic stroke]
I65.0 - I65.9	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction [acute or chronic cerebrovascular insufficiency]
I66.0 - I66.9	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction [acute or chronic cerebrovascular insufficiency]
I67. 1 - I67.2; I67.4 - I67.9	Other cerebrovascular diseases [acute or chronic cerebrovascular insufficiency/accident including thrombotic or embolic stroke]
I67.1 - I67.9	Other cerebrovascular diseases [coronary acute or chronic cerebrovascular insufficiency/accident including thrombotic or embolic stroke]
I67.81-I67.82	Acute or chronic cerebrovascular insufficiency
I87.2	Venous insufficiency (chronic) (peripheral) [venous stasis ulcer]
J43.0 - J43.9	Emphysema [pulmonary emphysema]
J44.0 - J44.9	Other chronic obstructive pulmonary disease [bronchitis with emphysema]
J68.0 - J68.9	Respiratory conditions due to inhalation of chemicals, gases, fumes and vapors [Acute thermal and chemical pulmonary damage, i.e., smoke inhalation with pulmonary insufficiency]
J70.0 - J70.9	Respiratory conditions due to other external agents [Acute thermal and chemical pulmonary damage, i.e., smoke inhalation (e.g., carbon tetrachloride, hydrogen sulfide) with pulmonary insufficiency]
K50.00 - K50.919	Crohn's disease [regional enteritis] [inflammatory bowel disease]
K52.0	Gastroenteritis and colitis due to radiation

K52.9	Noninfective gastroenteritis and colitis, unspecified [inflammatory bowel disease]
K71.10 - K71.11	Toxic liver disease with hepatic necrosis, without coma [hepatic necrosis]
K72.00 - K72.01	Acute and subacute hepatic failure
K76.2	Central hemorrhagic necrosis of liver [hepatic necrosis]
L40.52	Psoriatic arthritis mutilans [Arthritic diseases]
L55.0 - L55.9; L56.0 - L56.9; L57.0 - L57.1 - L57.9; L58.0 - L58.9; L59.0 - L59.9	Radiation - related disorders of the skin and subcutaneous tissue
L89.000 - L89.96	Pressure ulcers [decubitus ulcers], Pressured-induced deep tissue damage
M00.00 - M12.19; M12.50 - M19.93	Arthropathies [arthritic diseases]
M48.40xA - M48.58xS; M84.30xA - M84.759S; M96.621 - M96.69; M97.01xA - M97.9xxS; P13.0, P13.4, S02.0xxA - S02.92xS; S12.000A - S12.9xxS; S22.000A - S22.9xxS	Fractures
M79.7	Fibromyalgia
M80.00xA - M80.88xS	Osteoporosis with current pathological fracture
M81.0 - M81.8	Osteoporosis without current pathological fracture

N30.40	Irradiation cystitis without hematuria
R41.81	Age-related cognitive decline [senility]
R53.82	Chronic fatigue, unspecified
R57.0	Cardiogenic shock
S06.0x0A - S06.9x9S	Intracranial injury [traumatic brain injury]
T66.xxxA - T66.xxxS	Radiation sickness, unspecified
T81.30xA - T81.33xS	Disruption of wound [(surgical) wound dehiscence]
U07.1	COVID-19
U09.9	Post COVID-19 condition, unspecified
Z86.16	Personal history of COVID-19

CPT/HCPCS codes considered experimental or investigational:	
<i>Code</i>	<i>Description</i>
A4575	Topical hyperbaric oxygen chamber, disposable
E0446	Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories

References

1. Agarwal V, Aroor S, Gupta N, Gupta A, Agarwal N, Kaur N. New Technique of Applying Topical Oxygen Therapy as a Cost-Effective Procedure. *Indian J Surg.* 2015 Dec;77(Suppl 3):1456-9.
2. Agrawal, S. and N. Sharma, Complete recovery following hyperbaric oxygen therapy in idiopathic sudden sensorineural hearing loss--a report of two cases. *Undersea Hyperb Med,* 2016. 43(2): p. 161-6.
3. Armstrong, D.G. & J de Asla, R. (Jan 2021). *Management of diabetic foot ulcers.* UpToDate.com. https://www.uptodate.com/contents/management-of-diabetic-foot-ulcers?search=wagner%20grading%20scale&source=search_result&selectedTitle=7~150&usage_type=default&display_rank=7

4. Arslan A. (2021). Hyperbaric oxygen therapy in carbon monoxide poisoning in pregnancy: Maternal and fetal outcome. *The American Journal of Emergency Medicine*. 43, 41-45.
5. Bennett, M.H., et al., Hyperbaric oxygen therapy for acute ischaemic stroke. *Cochrane Database of Systematic Reviews*, 2014(11).
6. Bennett, M.H., et al., Hyperbaric oxygen therapy for late radiation tissue injury. *Cochrane Database of Systematic Reviews*, 2016(4).
7. Bennett, M.H., et al., Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache. *Cochrane Database of Systematic Reviews*, 2015(12).
8. Bennett, M.H., J.P. Lehm, and N. Jepson, Hyperbaric oxygen therapy for acute coronary syndrome. *Cochrane Database of Systematic Reviews*, 2015(7).
9. Bishop, A. J. (2015). Diabetic lower extremity ulcers and hyperbaric oxygen therapy. *J Endocrinol Diab*, 2(4), 1-5.
10. Borab, Z., Mirmanesh, M. D., Gantz, M., Cusano, A., & Pu, L. L. (2017). Systematic review of hyperbaric oxygen therapy for the treatment of radiation-induced skin necrosis. *Journal of Plastic, Reconstructive & Aesthetic Surgery*, 70(4), 529-538
11. Cardinal, J., Slade, A., McFarland, M., Keihani, S., Hotaling, J. N., & Myers, J. B. (2018). Scoping review and meta-analysis of hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. *Current urology reports*, 19, 1-8.
12. Casillas S, Galindo A, Camarillo-Reyes L A, et al. (October 15, 2019) Effectiveness of Hyperbaric Oxygenation Versus Normobaric Oxygenation Therapy in Carbon Monoxide Poisoning: A Systematic Review. *Cureus* 11(10): e5916. DOI 10.7759/cureus.5916
13. Celebi ARC. (2021). Hyperbaric Oxygen Therapy for Central Retinal Artery Occlusion: Patient Selection and Perspectives. *Clinical Ophthalmology*, 15, 3443-3457.
14. Clarke R. Monoplace chamber treatment of decompression illness: Review and commentary. *Diving Hyperb Med*. 2020 Sep 30;50(3):264-272. doi: 10.28920/dhm50.3.264-272. PMID: 32957129; PMCID: PMC7755460.
15. ClinicalTrials.gov. Hyperbaric Oxygen Therapy Effect on Post Concussion Syndrome in Children (TBIPED). NCT03339037. Retrieved from: <https://clinicaltrials.gov/ct2/show/NCT03339037>
16. Daly, S., Thorpe, M., Rockswold, S., Hubbard, M., Bergman, T., Samadani, U., & Rockswold, G. (2018). Hyperbaric oxygen therapy in the treatment of acute severe traumatic brain injury: a systematic review. *Journal of neurotrauma*, 35(4), 623-629.
17. Dryden M, Dickinson A, Brooks J, Hudgell L, Saeed K, Cutting KF. A multi-centre clinical evaluation of reactive oxygen topical wound gel in 114 wounds. *J Wound Care*. 2016 Mar;25(3):140-46.
18. Elraiyah, T., et al., A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers. *Journal of Vascular Surgery*, 2016. 63(2, Supplement): p. 46S-58S.e2.
19. Erdoğan, A., Düzgün, A. P., Erdoğan, K., Özkan, M. B., & Coşkun, F. (2018). Efficacy of hyperbaric oxygen therapy in diabetic foot ulcers based on Wagner classification. *The journal of foot and ankle surgery*, 57(6), 1115-1119.

20. Eskes, A., et al., Hyperbaric oxygen therapy for treating acute surgical and traumatic wounds. *Cochrane Database of Systematic Reviews*, 2013(12).
21. Fernández, E., Morillo, V., Salvador, M., Santafé, A., Beato, I., Rodríguez, M., & Ferrer, C. (2021). Hyperbaric oxygen and radiation therapy: a review. *Clinical and Translational Oncology*, 23(6), 1047-1053.
22. Fife CE, Eckert KA, Carter MJ. An Update on the Appropriate Role for Hyperbaric Oxygen: Indications and Evidence. *Plast Reconstr Surg*. 2016 Sep;138(3 Suppl):107S-16S.
23. Forner LE, Dieleman FJ, Shaw RJ, et al. (2021). Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. *Radiotherapy and Oncology*, 166, 137-144. Doi: <https://doi.org/10.1016/j.radonc.2021.11.021>
24. García-O'Farrill, N., Pugazhendhi, S., Karth, P. A., & Hunter, A. A. (2022, May). Radiation retinopathy intricacies and advances in management. In *Seminars in Ophthalmology* (Vol. 37, No. 4, pp. 417-435). Taylor & Francis.
25. Hadanny, A., et al., Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen. *Clinical Ophthalmology* (Auckland, N.Z.), 2017. 11: p. 115-125.
26. Harch, P. G. (2022). Systematic review and dosage analysis: hyperbaric oxygen therapy efficacy in mild traumatic brain injury persistent postconcussion syndrome. *Frontiers in neurology*, 160. Retrieved from: <https://www.frontiersin.org/articles/10.3389/fneur.2022.815056/full>
27. Harch, P. G., Andrews, S. R., Rowe, C. J., Lischka, J. R., Townsend, M. H., Yu, Q., & Mercante, D. E. (2020). Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trial. *Medical gas research*, 10(1), 8. Retrieved from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871939/>
28. Hayes, Inc. Health Technology Assessment. *Topical Oxygen Therapy For Chronic Wound Healing*. Lansdale, PA: Hayes, Inc.; Nov 21, 2017. Last annual review Jan 18, 2021.
29. Hayes, Inc. Health Technology Assessment. *Systemic Hyperbaric Oxygen Therapy for Post-concussive Syndrome in Adults*. Lansdale, PA: Hayes, Inc.;Sept 14, 2022.
30. Health Quality Ontario. (2017). Hyperbaric oxygen therapy for the treatment of diabetic foot ulcers: a health technology assessment. *Ontario health technology assessment series*, 17(5), 1.
31. Hosokawa, S., et al., Prognostic factors for idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy and intravenous steroids. *The Journal of Laryngology & Otology*, 2017. 131(1): p. 77-82.
32. Hu Q, Manaenko A, Xu T, Guo Z, Tang J, Zhang JH. Hyperbaric oxygen therapy for traumatic brain injury: bench-to-bedside. *Med Gas Res*. 2016 Jul 11;6(2):102-110. doi: 10.4103/2045-9912.184720. PMID: 27867476; PMCID: PMC5110132.
33. Huang, E., et al., A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. *Undersea Hyperb Med*, 2015. 42(3): p. 205-47.
34. Hyperbaric Oxygen (HBO₂) for COVID-19 Patients. UHMS Position Statement. *Undersea Hyperb Med*. April 8, 2020.

35. Jirangkul, P., Baisopon, S., Pandaeng, D., & Srisawat, P. (2021). Hyperbaric oxygen adjuvant therapy in severe mangled extremities. *Injury*, 52(11), 3511-3515.
36. Johnson-Arbor, K., & Cooper, J. S. (2017). Hyperbaric Therapy In Blood Loss Anemia.
37. Joshua TG, Ayub A, Wijesinghe P, Nunez DA. Hyperbaric Oxygen Therapy for Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. *JAMA Otolaryngol Head Neck Surg*. 2022;148(1):5–11. doi:10.1001/jamaoto.2021.2685
38. Kirby, J. P., Snyder, J., Schuerer, D. J. E., Peters, J. S., & Bochicchio, G. V. (2019). Essentials of Hyperbaric Oxygen Therapy: 2019 Review. *Missouri medicine*, 116(3), 176–179
39. Kranke, P., et al., Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database of Systematic Reviews*, 2015(6).
40. Kutz C.J., Kirby I.J., Grover I.R., et al. (2023). Aviation Decompression Sickness in Aerospace and Hyperbaric Medicine. *Aerospace Medicine and Human Performance*, 94(1), 11-17.
41. Liu, R., et al., Systematic Review of the Effectiveness of Hyperbaric Oxygenation Therapy in the Management of Chronic Diabetic Foot Ulcers. *Mayo Clinic Proceedings*, 2013. 88(2): p. 166-175.
42. Mathieu, D., Marroni, A., & Kot, J. (2017). Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. *Diving and hyperbaric medicine*, 47(1), 24.
43. Margolis DJ., et al., Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. *Diabetes Care*. 2013;36(7):1961.
44. Martin, R., et al., Using hyperbaric oxygen for autism treatment: A review and discussion of the literature. *Undersea Hyperb Med*, 2015. 42(4): p. 353-9.
45. Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. *Diving Hyperb Med*. 2017 Mar;47(1):24-32.
46. Memar, M. Y., Yekani, M., Alizadeh, N., & Baghi, H. B. (2019). Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections. *Biomedicine & Pharmacotherapy*, 109, 440-447.
47. Mladenov, A., Diehl, K., Müller, O., von Heymann, C., Kopp, S., & Peitsch, W. K. (2022). Outcome of necrotizing fasciitis and Fournier's gangrene with and without hyperbaric oxygen therapy: a retrospective analysis over 10 years. *World Journal of Emergency Surgery*, 17(1), 43.
48. Moon, R., Hyperbaric oxygen treatment for air or gas embolism. *Undersea Hyperb Med*, 2014. 41(2): p. 159-66.
49. Oley MH, Oley MC, Noersasongko AD, et al. (2021) Effects of hyperbaric oxygen therapy on vascular endothelial growth factor protein and mRNA in crush injury patients: A randomized controlled trial study. *International Journal of Surgery Open*, 29, 33-39. Doi: <https://doi.org/10.1016/j.ijso.2021.01.003>
50. Ortega, M. A., Fraile-Martinez, O., García-Montero, C., Callejón-Peláez, E., Sáez, M. A., Álvarez-Mon, M. A., ... & Canals, M. L. (2021). A general overview on the hyperbaric oxygen therapy: applications, mechanisms and translational opportunities. *Medicina*, 57(9), 864.

51. Pereira D., Ferreira C., Catarino R, et al. Hyperbaric oxygen for radiation-induced cystitis: A long-term follow-up, *Actas Urológicas Españolas (English Edition)*, Volume 44, Issue 8, 2020, Pages 561-567, ISSN 2173-5786, doi: <https://doi.org/10.1016/j.acuroe.2020.03.004>.
52. Phillips, J.S. and S.E.M. Jones, Hyperbaric oxygen as an adjuvant treatment for malignant otitis externa. *Cochrane Database of Systematic Reviews*, 2013(5).
53. Sayadi, L.R., Banyard, D.A., & Ziegler, M.E., et al. (Jan 2018). Topical oxygen therapy & micro/nanobubbles: a new modality for tissue oxygen delivery. *International Wound Journal*, 15 (3), 363-374. Doi: <https://doi.org/10.1111/iwj.12873>
54. Sen S, Sen S. Therapeutic effects of hyperbaric oxygen: integrated review. *Med Gas Res*. 2021 Jan-Mar;11(1):30-33. doi: 10.4103/2045-9912.310057. PMID: 33642335; PMCID: PMC8103971.
55. Sharma, R., Sharma, S. K., Mudgal, S. K., Jelly, P., & Thakur, K. (2021). Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. *scientific reports*, 11(1), 1-12.
56. U.S. Food & Drug Administration. Hyperbaric Oxygen Therapy: Get the Facts. Last updated July 26, 2021. Retrieved from: https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts?utm_medium=email&utm_source=govdelivery
57. Vann, R.D., et al., Decompression illness. *The Lancet*. 377(9760): p. 153-164.
58. Xiong, T., et al., Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). *Cochrane Database of Systematic Reviews*, 2016(10).
59. Moon, R. E., & Mitchell, S. J. (2021). Hyperbaric oxygen for decompression sickness. *Undersea & hyperbaric medicine: journal of the Undersea and Hyperbaric Medical Society, Inc*, 48(2), 195-203.
60. Yu J, Lu S, McLaren AM, Perry JA, Cross KM. Topical oxygen therapy results in complete wound healing in diabetic foot ulcers. *Wound Repair Regen*. 2016 Nov;24(6):1066-1072.
61. Indications for Hyperbaric Oxygen Therapy: 14th Edition. Undersea and Hyperbaric Medical Society. Published 2019. Available from: <https://www.uhms.org/resources/hbo-indications.html>.
62. Hyperbaric Oxygen Therapy for Mild Traumatic Brain Injury. US Department of Defense. Report in response to Senate report 113-44, pages 132-133, to accompany S. 1197, The National Defence Authorization Act of Fiscal Year 2014; January 2018. Available from: <https://health.mil/Reference-Center/Reports/2018/01/29/Hyperbaric-Oxygen-Therapy-for-Mild-Traumatic-Brain-Injury/>.
63. Sultan A, et al. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. *The Oncologist* 2017;22:343–350. <http://doi.org/10.1634/theoncologist.2016-0298>
64. Sun XK, Li R, Yang XL, Yuan L. Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: An updated systematic review and meta-analysis. *International Wound Journal*, 19 (8), 2200-2209. Doi: <https://doi.org/10.1111/iwj.13830>

65. Villeirs L, Taily T, Ost P, et al. Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: Systematic review of the recent literature. *International Journal of Urology*, 27(2), 98-107.
66. Yip LT, Au SCL, Ko CKL. Hyperbaric oxygen therapy for central retinal artery occlusion: experience in Hong Kong. *Hong Kong J Ophthalmol* [Internet]. 2020 Dec.22 [cited 2023May9];24(2). Available from: <https://www.hkjo.hk/index.php/hkjo/article/view/281>

Clinical Guideline Revision / History Information

Original Date: 8/7/2017

Reviewed/Revised: 1/18/2018, 7/31/2018, 7/23/2019, 7/21/2020, 8/4/2021, 12/01/2021, 07/26/2022, 07/19/2023